RxDoctor Payments Data

Karen McNeely, NP

Nurse Practitioner · Statesboro, GANPI 1104228402

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 55 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$603
  • UCB, Inc.$215
  • Lilly USA, LLC$78
  • LEO Pharma Inc.$74
  • Dermavant Sciences, Inc.$71
  • Biofrontera Inc.$39
  • plus $160 from 8 others

What the payments were for

  • Food & beverage$1,23299%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$122,323
Medicare patients
340
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz SyringeIxekizumab13$88,106
OtezlaApremilast19$87,025
Taltz AutoinjectorIxekizumab12$83,413
Fluorouracil97$5,838
Clobetasol Propionate117$3,487
Ketoconazole105$1,536
Azelaic Acid12$1,276
Imiquimod46$1,189
Mupirocin167$1,113
Metronidazole20$1,010
Desonide25$757
Clindamycin Phosphate17$726
Doxycycline Monohydrate35$588
Nystatin23$322
Triamcinolone Acetonide48$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$19$87,02519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →